红塔红土医药精选股票发起式A(020331)财务指标
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 本期已实现收益 |
-692,427.86 |
2,441,623.81 |
630,669.70 |
442,087.12 |
| 本期利润 |
-1,462,229.08 |
2,790,310.42 |
1,533,332.27 |
-176,708.09 |
| 加权平均基金份额本期利润 |
-0.14 |
0.27 |
0.15 |
-0.02 |
| 本期加权平均净值利润率(%) |
-12.82 |
23.68 |
13.94 |
-1.78 |
| 本期基金份额净值增长率(%) |
-12.26 |
26.89 |
15.35 |
-1.73 |
| 期末可供分配利润 |
91,730.26 |
1,539,844.41 |
1,066,580.51 |
-176,143.99 |
| 期末可供分配基金份额利润 |
0.01 |
0.15 |
0.10 |
-0.02 |
| 期末基金资产净值 |
10,489,121.13 |
11,829,418.27 |
11,666,298.41 |
10,016,499.60 |
| 期末基金份额净值 |
1.01 |
1.15 |
1.13 |
0.98 |
| 基金份额累计净值增长率(%) |
9.41 |
24.70 |
13.35 |
-1.73 |